The Technical Analyst
Select Language :
BeyondSpring Inc [BYSI]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

BeyondSpring Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

BeyondSpring Inc is listed at the  Exchange

-1.65% $3.57

America/New_York / 28 mar 2024 @ 16:00


BeyondSpring Inc: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 139.29 mill
EPS: -0.710
P/E: -5.03
Earnings Date: Mar 28, 2024
SharesOutstanding: 39.02 mill
Avg Daily Volume: 0.210 mill
RATING 2024-03-28
B+
Neutral
RATINGS
Rating CashFlow: Strong Sell
Return On Equity: Neutral
Return On Asset: Buy
DE: Sell
P/E: Strong Buy
Price To Book: Neutral
QUARTER GROWTHS
2/223/224/221/232/233/23
Revenuen/an/an/an/an/a
Gr.Profitn/an/an/an/an/a
Ebitn/an/an/an/an/a
Asset n/an/an/a
Debtn/an/an/a
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -5.03 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.86x
Company: PE -5.03 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$-0.644
(-118.03%) $-4.21
Date: 2024-03-28
Expected Trading Range (DAY)

$ 3.21 - 3.93

( +/- 10.06%)
ATR Model: 14 days

Forecast: 16:00 - $3.56

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $3.56
Forecast 2: 16:00 - $3.56
Forecast 3: 16:00 - $3.56
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $3.57 (-1.65% )
Volume 0.157 mill
Avg. Vol. 0.210 mill
% of Avg. Vol 74.97 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for BeyondSpring Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for BeyondSpring Inc

RSI

Intraday RSI14 chart for BeyondSpring Inc

Last 10 Buy & Sell Signals For BYSI

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            BeyondSpring Inc

BYSI

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

Last 10 Buy Signals

Date Signal @
KUBUSDMar 28 - 19:082.69
FISUSDMar 28 - 19:030.952
PROPCUSDMar 28 - 18:585.09
XCADUSDMar 28 - 18:571.490
INDEXUSDMar 28 - 18:565.95
FUMOUSDMar 28 - 18:5410 001
ALPHUSDMar 28 - 18:542.71
HNTUSDMar 28 - 18:47$6.19
WBTUSDMar 28 - 18:438.37
TRXUSDMar 28 - 18:39$0.120

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.